Novel BMP2 antagonist inhibitors for bone graft substitution
Recombinant bone morphogenetic protein 2 (BMP-2) is a known bone graft substitute used in the treatment of bone fractures and bone defects and is currently available on the market. BMP-2 must be applied in high concentrations to induce bone formation in clinical settings. Its limited therapeutic efficacy may be due to the presence of BMP antagonists that neutralize exogenous BMP-2. Inventors at the University of Würzburg (Germany) have identied a novel inactive BMP-2 mutein, named L51P, which acts as an inhibitor of BMP antagonists noggin, chordin and gremlin. In vitro and in vivo validation studies with a combination of BMP-2 and L51P led to a signi cant increase in BMP activity.
BMP-2 and other members of the TGF-b superfamily regulate the development, maintenance and regeneration of many tissues and organs. Dysregulation of BMP and TGF-b signalling is critical during several disorders including fibrosis, osteoporosis, cancer, arthritis and bone or cartilage repair.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…
